^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    ESG401

    i
    Other names: ESG401, ESG 401, ESG-401, Anti-Trop-2 ADC, STI-3258, STI3258, STI 3258
    Company:
    Escugen Biotechnology, Sorrento
    Drug class:
    Topoisomerase I inhibitor, TROP-2-targeted antibody-drug conjugate
    Related drugs:
    4ms
    A Phase III Study of ESG401 for Locally Advanced or Metastatic HR+/HER2- Breast Cancer (clinicaltrials.gov)
    P3, N=378, Recruiting, Shanghai Escugen Biotechnology Co., Ltd | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    gemcitabine • capecitabine • Halaven (eribulin mesylate) • vinorelbine tartrate • ESG401
    7ms
    A Phase III Study of ESG401 for Locally Advanced or Metastatic HR+/HER2- Breast Cancer (clinicaltrials.gov)
    P3, N=378, Not yet recruiting, Shanghai Escugen Biotechnology Co., Ltd
    New P3 trial • Metastases
    |
    gemcitabine • capecitabine • Halaven (eribulin mesylate) • vinorelbine tartrate • ESG401
    8ms
    Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing (clinicaltrials.gov)
    P2, N=30, Recruiting, Peking Union Medical College | Initiation date: Dec 2023 --> May 2024
    Trial initiation date • Metastases
    |
    cisplatin • erlotinib • carboplatin • sorafenib • AiTan (rivoceranib) • albumin-bound paclitaxel • abiraterone acetate • bicalutamide • larotinib (Z650) • ESG401 • Entyvio (vedolizumab)
    11ms
    Study of ESG401 in Adults With Solid Tumors (clinicaltrials.gov)
    P1/2, N=177, Recruiting, Shanghai Escugen Biotechnology Co., Ltd
    Trial completion date • Trial primary completion date • Metastases
    |
    ESG401